评估磁共振肿瘤消退分级(mrTRG)作为新生物标志物按放化疗反应好坏分层管理的直肠癌可行性研究(TRIGGER):一项随机对照试验的研究方案
TRIGGER是一项多中心、开放、干预性随机对照可行性研究,嵌入III期试验设计,纳入MRI定义局部晚期直肠腺癌需放化疗患者,按1:2随机分为常规管理和mrTRG导向管理,主要终点为招募和随机化率,可行性阶段结果将指导III期试验设计。
要点
- TRIGGER研究评估mrTRG导向管理 feasibility,主要终点为患者招募和随机化率。
- 患者按1:2随机分为常规管理组和mrTRG导向管理组。
- 可行性阶段结果将用于设计III期试验,关注3年无病生存和免造口生存。
核心结论
- TRIGGER试验旨在确定局部晚期直肠癌患者能否被招募并随机进入一项根据放化疗后影像学反应(mrTRG)提供MRI导向管理的对照试验。
- 可行性研究将为III期试验设计提供信息,该III期试验根据3年无病生存、免造口生存以及无重大切除病例增加来研究对好和差反应者的分层治疗。
研究设计与样本
- TRIGGER是一项多中心、开放、干预性随机对照可行性研究,嵌入III期试验设计。
- 纳入MRI定义局部晚期直肠腺癌且被认为需要放化疗的患者。
- 在放化疗期间,患者按1:2随机分为根据基线MRI的常规管理组与mrTRG导向管理组。
主要发现
- 可行性阶段的主要终点是评估患者招募和随机化率。
- 次要终点包括单位招募率、急性药物毒性、mrTRG报告的可重复性、手术并发症、病理环周切缘受累、病理消退分级、残留肿瘤细胞密度和手术/标本质量率。
- III期试验将关注长期安全性、再生长率、肿瘤学生存分析、生活质量和健康经济学分析。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-operative chemoradiotherapy (CRT) for MRI-defined, locally advanced rectal cancer is primarily intended to reduce local recurrence rates by downstaging tumours, enabling an improved likelihood of curative resection. However, in a subset of patients complete tumour regression occurs implying that no viable tumour is present within the surgical specimen. This raises the possibility that surgery may have been avoided. It is also recognised that response to CRT is a key determinant of prognosis. Recent radiological advances enable this response to be assessed pre-operatively using the MRI tumour regression grade (mrTRG). Potentially, this allows modification of the baseline MRI-derived treatment strategy. Hence, in a 'good' mrTRG responder, with little or no evidence of tumour, surgery may be deferred. Conversely, a 'poor response' identifies an adverse prognostic group which may benefit from additional pre-operative therapy. METHODS/DESIGN: TRIGGER is a multicentre, open, interventional, randomised control feasibility study with an embedded phase III design. Patients with MRI-defined, locally advanced rectal adenocarcinoma deemed to require CRT will be eligible for recruitment. During CRT, patients will be randomised (1:2) between conventional management, according to baseline MRI, versus mrTRG-directed management. The primary endpoint of the feasibility phase is to assess the rate of patient recruitment and randomisation. Secondary endpoints include the rate of unit recruitment, acute drug toxicity, reproducibility of mrTRG reporting, surgical morbidity, pathological circumferential resection margin involvement, pathology regression grade, residual tumour cell density and surgical/specimen quality rates. The phase III trial will focus on long-term safety, regrowth rates, oncological survival analysis, quality of life and health economics analysis. DISCUSSION: The TRIGGER trial aims to determine whether patients with locally advanced rectal cancer can be recruited and subsequently randomised into a control trial that offers MRI-directed patient management according to radiological response to CRT (mrTRG). The feasibility study will inform a phase III trial design investigating stratified treatment of good and poor responders according to 3-year disease-free survival, colostomy-free survival as well as an increase in cases managed without a major resection. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02704520 . Registered on 5 February 2016.
引用
- Battersby NJ, Dattani M, Rao S, et al. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials. 2017. PMID: 28851403. doi:10.1186/s13063-017-2085-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。